Watch Dr Errol De Souza, Executive Chairman of Bionomics (ASX:BNO | OTCQB:BNOEF) explain about Bionomics recent drug developments, successful capital raise as well as its recent collaboration with EmpathBio.
0:00 – StockPal Introductions
0:11 • Firstly, can you tell us about the area of drug development Bionomics is focused on?
0:27 • Bionomics recently completed a $16m capital raise to progress BNC210 for PTSD. How will this money be used?
1:05 • The capital raise attracted some big investors such as Paypal co-founder Peter Thiel. Why do you think BNC210 has drawn such interest?
1:49 • Bionomics recently entered into collaboration with EmpathBio to study BNC210 and an MDMA derivative in treating PTSD. How is this approach different from the current standard of care?
3:06 • Could you tell us more about Bionomics’ intellectual property portfolio and how this protects investors in the long run?
3:32 • Lastly, what are your top priorities for the year ahead and what key milestones do investors have to look forward to?
Visit Bionomics’ website to learn more about their story:
Email email@example.com if you are or represent a listed-company and is keen to be in our interviews.